This is the first instalment of my three-part investigative report on the Chinese-made Innova lateral flow test. Vast sums of UK taxpayers’ money have been paid to a California start-up for tests that have failed to stand up to scrutiny.
…Innova Medical Group, the company benefiting from the UK Government’s huge testing contract, is owned by the private equity group Pasaca Capital which was founded by a Chinese investment banker, the enigmatic Dr Charles Huang, in 2017. It has been revealed to be the single largest recipient of the Department of Health’s Covid contracts after signing a £496million deal to supply LFTs last year. An earlier contract with Innova cost the taxpayer £107million.
Recently, the Government agreed a £161 million deal with a British company called DnaNudge to provide 5.8 million Covid tests, as part of its “Moonshot” programme for mass testing of the population at the point of care. The CovidNudge test is “a rapid, accurate, portable and lab-free RT-PCR test that delivers results at the point of need and in just over an hour”, according to DnaNudge’s own promotional material. DnaNudge is a spinoff company of Imperial College London.